ES2195943T3 - Compuestos heteroaromaticos biciclicos y triciclicos. - Google Patents

Compuestos heteroaromaticos biciclicos y triciclicos.

Info

Publication number
ES2195943T3
ES2195943T3 ES00977138T ES00977138T ES2195943T3 ES 2195943 T3 ES2195943 T3 ES 2195943T3 ES 00977138 T ES00977138 T ES 00977138T ES 00977138 T ES00977138 T ES 00977138T ES 2195943 T3 ES2195943 T3 ES 2195943T3
Authority
ES
Spain
Prior art keywords
sub
compounds
triciclic
bicycle
heteroaromatic compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00977138T
Other languages
English (en)
Inventor
Jun Yuan
Pamela Albaugh
Kenneth Shaw
Alan Hutchison
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurogen Corp
Original Assignee
Neurogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurogen Corp filed Critical Neurogen Corp
Application granted granted Critical
Publication of ES2195943T3 publication Critical patent/ES2195943T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto de fórmula **fórmula** o una sal farmacéuticamente aceptable del mismo, en la que: X representa N o CR1, en la que R1 es hidrógeno, halógeno, hidroxi, ciano, nitro, amino, alquilo C1-C6, alcoxi C1-C6, trifluorometilo, trifluorometoxi, mono- o dialquil(C1-C6)amino o aminoalquilo C1-C6; X1 representa N, CH o alquilo C1-C6; Y y Z son independientemente hidrógeno, halógeno, hidroxi, ciano, nitro, amino, alquilo C1-C6, alcoxi C1-C6, trifluorometilo, trifluorometoxi, mono- o dialquil(C1-C6)amino o aminoalquilo C1-C6; o Y y Z forman juntos un anillo de arileno o un anillo de cicloalquileno C3-C8, cada uno de los cuales está sustituido opcionalmente con hasta cuatro grupos R2 seleccionados independientemente en cada caso entre halógeno, hidroxi, ciano, nitro, amino, alquilo C1- C6, alcoxi C1-C6, trifluorometilo, trifluorometoxi, mono- o dialquil(C1-C6)amino y aminoalquilo C1-C6.
ES00977138T 1999-11-12 2000-11-10 Compuestos heteroaromaticos biciclicos y triciclicos. Expired - Lifetime ES2195943T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16505499P 1999-11-12 1999-11-12

Publications (1)

Publication Number Publication Date
ES2195943T3 true ES2195943T3 (es) 2003-12-16

Family

ID=22597230

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00977138T Expired - Lifetime ES2195943T3 (es) 1999-11-12 2000-11-10 Compuestos heteroaromaticos biciclicos y triciclicos.

Country Status (16)

Country Link
US (4) US6511987B1 (es)
EP (1) EP1228069B1 (es)
JP (1) JP2003513975A (es)
KR (1) KR20020050262A (es)
CN (1) CN1390217A (es)
AT (1) ATE236158T1 (es)
AU (1) AU1481701A (es)
BR (1) BR0015420A (es)
CA (1) CA2388593A1 (es)
DE (1) DE60001983T2 (es)
ES (1) ES2195943T3 (es)
IL (1) IL149550A0 (es)
MX (1) MXPA02004735A (es)
NO (1) NO20022185D0 (es)
WO (1) WO2001034603A2 (es)
ZA (1) ZA200203653B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1481701A (en) 1999-11-12 2001-06-06 Neurogen Corporation Bicyclic and tricyclic heteroaromatic compounds
US6833377B2 (en) 2001-02-05 2004-12-21 Gevys Pharmaceuticals Ltd. Composition and method for potentiating drugs
FR2823752B1 (fr) * 2001-04-18 2004-10-22 Servier Lab Nouveaux derives de pyrimidin-4-ones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
US6921762B2 (en) 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
KR20050090435A (ko) 2002-12-30 2005-09-13 셀진 코포레이션 플루오로알콕시-치환된 1,3-디히드로-이소인돌릴 화합물 및그의 제약학적 용도
WO2005025563A1 (en) * 2003-09-12 2005-03-24 Warner-Lambert Company Llc Combination comprising an alpha-2-delta ligand and an ssri and/or snri for treatment of depression and anxiety disorders
US7546431B2 (en) * 2005-03-21 2009-06-09 Emc Corporation Distributed open writable snapshot copy facility using file migration policies
RS55630B1 (sr) 2005-12-21 2017-06-30 Janssen Pharmaceutica Nv Triazolopiridazini kao modulatori tirozin kinaze
ATE537171T1 (de) 2005-12-27 2011-12-15 Hoffmann La Roche Aryl-isoxazol-4-yl-imidazoä1,5-aüpyridin-deriva e
KR101119365B1 (ko) 2006-05-31 2012-03-07 에프. 호프만-라 로슈 아게 아릴-4-에틴일-아이속사졸 유도체
US7683060B2 (en) 2006-08-07 2010-03-23 Incyte Corporation Triazolotriazines as kinase inhibitors
SI2074123T1 (sl) 2006-10-16 2013-03-29 Bionomics Limited Nove anksiolitične spojine
US10954231B2 (en) 2006-10-16 2021-03-23 Bionomics Limited Anxiolytic compounds
GEP20125658B (en) 2006-11-22 2012-10-10 Incyte Corp Imidazotriazines and imidazo pyrimidines as kinase inhibitors
CN101965344B (zh) 2007-06-22 2013-03-06 弗·哈夫曼-拉罗切有限公司 异*唑-咪唑衍生物
US7902201B2 (en) 2007-12-04 2011-03-08 Hoffmann-La Roche Inc. Isoxazolo-pyrazine derivatives
US7618973B2 (en) 2007-12-04 2009-11-17 Hoffmann-La Roche Inc. Isoxazolo-pyrazine derivatives
US7943619B2 (en) 2007-12-04 2011-05-17 Hoffmann-La Roche Inc. Isoxazolo-pyridazine derivatives
WO2009082691A1 (en) * 2007-12-21 2009-07-02 Board Of Regents, University Of Texas System Dihydroorotate dehydrogenase inhibitors with selective anti-malarial activity
SI2300455T1 (sl) 2008-05-21 2017-12-29 Incyte Holdings Corporation Soli 2-fluoro-n-metil-4-(7-(kinolin-6-il-metil)-imidazo(1,2-b)1,2,4) triazin-2-il)benzamid in postopki v zvezi z njihovo pripravo
US8895550B2 (en) 2008-08-19 2014-11-25 Array Biopharma Inc. Triazolopyridine compounds as PIM kinase inhibitors
TWI496779B (zh) 2008-08-19 2015-08-21 Array Biopharma Inc 作為pim激酶抑制劑之三唑吡啶化合物
WO2010022081A1 (en) 2008-08-19 2010-02-25 Array Biopharma Inc. Triazolopyridine compounds as pim kinase inhibitors
TW201033201A (en) 2009-02-19 2010-09-16 Hoffmann La Roche Isoxazole-isoxazole and isoxazole-isothiazole derivatives
US8389550B2 (en) 2009-02-25 2013-03-05 Hoffmann-La Roche Inc. Isoxazoles / O-pyridines with ethyl and ethenyl linker
US8222246B2 (en) 2009-04-02 2012-07-17 Hoffmann-La Roche Inc. Substituted isoxazoles
US8227461B2 (en) 2009-04-30 2012-07-24 Hoffmann-La Roche Inc. Isoxazoles
US8415379B2 (en) 2009-05-05 2013-04-09 Hoffmann-La Roche Inc. Pyridines
BRPI1014454A2 (pt) 2009-05-05 2016-04-05 Hoffmann La Roche derivados de isoxazol-pirazol
BRPI1013762A2 (pt) 2009-05-05 2015-08-25 Hoffmann La Roche "derivados isoxazol-piridazina"
ES2601181T3 (es) 2009-05-05 2017-02-14 F. Hoffmann-La Roche Ag Derivados de isoxazol-tiazol como agonistas inversos del receptor GABA A para su uso en el tratamiento de trastornos cognitivos
KR101354416B1 (ko) 2009-05-07 2014-02-19 에프. 호프만-라 로슈 아게 감마-아미노부티르산 조절제로서 이속사졸-피리딘 유도체
MX2012008898A (es) 2010-02-03 2012-11-06 Incyte Corp Imidazo - [1, 2 - b] [1, 2, 4] triazinas como inhibidores de c - met.
MX339899B (es) 2011-02-25 2016-06-16 Array Biopharma Inc Compuestos de triazolopiridina como inhibidores de pim cinasa.
WO2012116415A1 (en) 2011-03-02 2012-09-07 Bionomics Limited Novel small-molecules as therapeutics
CN103649086A (zh) 2011-05-12 2014-03-19 生态学有限公司 制备萘啶的方法
US8785435B2 (en) 2011-10-20 2014-07-22 Hoffmann-La Roche Inc. Solid forms
US20150374705A1 (en) 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain
CN106854207B (zh) * 2015-12-08 2019-10-29 上海赛默罗生物科技有限公司 呔嗪类衍生物、其制备方法、药物组合物和用途
JP7351590B2 (ja) * 2018-03-12 2023-09-27 シャンハイ エスアイエムアール バイオテクノロジー カンパニー リミテッド フタラジンイソオキサゾールアルコキシ誘導体、その製造方法、薬物組成物および使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1194310B (it) * 1983-07-12 1988-09-14 Lepetit Spa Derivati triazolo (3,4-a) ftalazinici 3,6-disostituiti
IT1270615B (it) * 1994-07-14 1997-05-07 Smithkline Beecham Farma Uso di derivati di chinolina
US5955465A (en) 1996-03-22 1999-09-21 Neurogen Corporation 1,2,4-triazolo 4,3-c!quinazolin-3-ones and 1,2,4-triazolo 4,3-c!quinazolin-3-thiones
GB9715977D0 (en) * 1997-07-29 1997-10-01 Merck Sharp & Dohme Therapeutic agents
US6297235B1 (en) 1997-08-28 2001-10-02 Merck Sharp & Dohme Ltd. Triazolopyridazine derivatives for treating anxiety and enhancing cognition
AU746866B2 (en) 1998-01-14 2002-05-02 Merck Sharp & Dohme Limited Triazolo-pyridazine derivatives as ligands for GABA receptors
WO1999050385A2 (en) 1998-03-30 1999-10-07 President And Fellows Of Harvard College Regulation of glycosaminoglycan synthesis, methods and reagents related thereto
ATE247652T1 (de) * 1999-03-29 2003-09-15 Neurogen Corp 4-substituierte chinolinderivate als nk-3 und/oder gaba(a) rezeptor liganden
AU1481701A (en) 1999-11-12 2001-06-06 Neurogen Corporation Bicyclic and tricyclic heteroaromatic compounds

Also Published As

Publication number Publication date
US20080146546A1 (en) 2008-06-19
JP2003513975A (ja) 2003-04-15
DE60001983T2 (de) 2004-01-29
US20030181455A1 (en) 2003-09-25
ATE236158T1 (de) 2003-04-15
US20060217384A1 (en) 2006-09-28
US7053093B2 (en) 2006-05-30
DE60001983D1 (de) 2003-05-08
BR0015420A (pt) 2002-07-16
KR20020050262A (ko) 2002-06-26
NO20022185L (no) 2002-05-07
NO20022185D0 (no) 2002-05-07
CA2388593A1 (en) 2001-05-17
EP1228069A2 (en) 2002-08-07
US6511987B1 (en) 2003-01-28
ZA200203653B (en) 2003-04-10
CN1390217A (zh) 2003-01-08
AU1481701A (en) 2001-06-06
WO2001034603A2 (en) 2001-05-17
US7326709B2 (en) 2008-02-05
EP1228069B1 (en) 2003-04-02
WO2001034603A3 (en) 2002-01-10
IL149550A0 (en) 2002-11-10
MXPA02004735A (es) 2003-01-28

Similar Documents

Publication Publication Date Title
NO20022185D0 (no) Bisykliske og trisykliske heteroaromatiske forbindelser
WO2002002557A3 (en) 2-phenylimidazo[1,2-a]pyridine derivatives: a new class of gaba brain receptor ligands
PT1259489E (pt) Compostos azapoliciclicos condensados con arilo.
SE9904508D0 (sv) New compounds
EA200300293A1 (ru) Противовоспалительные конденсированные пирролокарбазолы
GC0000375A (en) Benzodiazepine derivatives as gaba a receptor modulators
EA200300528A1 (ru) 1-арил-или 1-алкилсульфонилгетероциклилбензазолы в качестве лигандов 5-гидрокситриптамина-6
BG66085B1 (bg) Фенилаланинови производни
ATE261448T1 (de) Heteroaryl diazabicycloalkene, deren herstellung und verwendung
ATE377602T1 (de) Morphinanderivate und ihre medizinische anwendung
EA200300716A1 (ru) Гетероциклилалкилиндольные или -азаиндольные соединения в качестве лиганд 5-гидрокситриптамина-6
SE0102055D0 (sv) New Compounds
CA2354606A1 (en) Azabicycloalkane derivatives and therapeutic uses thereof
DE69914935D1 (de) 8-azabicyclo[3.2.1]okt-2-en- und -oktanderivate
EA200100301A3 (ru) НОВЫЙ СПОСОБ ПОЛУЧЕНИЯ 11-АМИНО-3-ХЛОР-6,11-ДИГИДРО-5,5-ДИОКСО-6-МЕТИЛДИБЕНЗО[c,f][1,2]ТИАЗЕПИНА И ЕГО ПРИМЕНЕНИЕ ДЛЯ СИНТЕЗА ТИАНЕПТИНА
EA200000996A1 (ru) Конденсированные с арилом азаполициклические соединения
ID28601A (id) Proses penyiapan senyawa-senyawa 1,4-dihidropiridin
RU94046144A (ru) Замещенные (арилалкиламинобензил) аминопропионамидные производные, их применение, способы их получения, фармкомпозиция
ATE216233T1 (de) Indolditerpen alkaloide
DE60227113D1 (de) Kondensierte camptothecine als antitumormittel
EP1172106A3 (en) Use of fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles as substance P receptor antagonists
SG165152A1 (en) Chemokine receptor antagonists and methods of use thereof
FR2805535B1 (fr) Nouveau procede de preparation de l'isoindoline
ATE258934T1 (de) Azaindol derivate und ihre verwendung als antithrombotische wirkstoffe
BR9810031A (pt) Derivados de ácido pirrolidina carboxìlico como antagonistas á endotelina